Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
Health economic and outcomes research datasets have rarely been integral to product development and communication plans.
The Ketchum veteran joined the nonprofit healthcare system in mid-2014.
Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.
Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet
Recent polls paint a mixed picture of physicians' willingness to see pharma sales reps. What gives? Are no-see docs up or down, and what's behind the dissonant findings?
After Bill McEllen's departure, the company promoted Mark Willmann to lead the agency.
FitzPatrick is departing the company as it evaluates its 150 agency partnerships.
Now that payers are locking in discounts at launch from drugmakers, where do co-pay cards fit in the marketing mix?
A pharma research forefather. An agency builder. A "guy you wanted in the room." These Medical Advertising Hall of Fame inductees are a professionally diverse and richly worthy trio.
Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets
The idea that 30 days is enough time for the FDA to evaluate anything is, of course, quite silly. But Sen. Cruz takes it one step further.
Click for an infographic to learn more about orphan drugs, rare diseases and the top-selling drugs in the category.
Gleevec generics hit shelves; four OxyContin patents are invalidated; Sanofi axes 600 positions
Plus other industry hires and changes
- Five things for pharma marketers to know: Friday, February 5, 2016
- Why Gathering Health Economic Data for Cancer Drugs is Now Essential
- Ascension Health ups Ragone to chief marcomms officer
- House Oversight committee upbraids Turing, Valeant execs
- Burcin departs Havas network for Klick Health in senior-staffing push